BOSTON ( TheStreet) -- This is the last Biotech Stock Mailbag column in 2010. Call me a slacker but I'm exercising my right to give the Mailbag a much-needed holiday rest.
Before I get to your biotech stock questions and comments, let me take this opportunity to thank all of you for making the Mailbag -- now entering its fifth (!) year -- such an meaningful anchor in TheStreet's coverage of the biotech sector.
My personal feelings about the Mailbag and pretty much everything I try to do at TheStreet were summed up best in a recent email I received from David K.:
"I wanted to thank you again for replying to my comments in this week's Biotech Stock Mailbag article. Even if I don't always agree with your opinions or presentation of information, I am interested in what you have to contribute and I keep abreast of your work daily. One of the first items I read every morning is your column."I believe that you taking the time to interact with readers in the comments section of your articles or in a live discussion during panel hearings says a great deal about your work ethic. You are surely committed to providing readers, both friends and foes alike, an opportunity to actually be a part of your column. You create a sense of community (even if a hostile one) through making your column dynamic as opposed to other authors whose static blogs simply post an article and nothing more. Your efforts are commendable and I encourage you to keep up the good work." Makes me blush. Thank you, David, for the very kind words, even though I like to think that I'm not the one instigating the hostilities. When pushed, however, I will push back. I truly appreciate all the readers of this Mailbag, my columns and stories. That includes those of you who desperately need spell check (once again, it's l-o-s-e-r, not l-o-o-s-e-r) and even the die-hard conspiracy theorists who will never stop believing that I'm banking coin from hedge fund short sellers in an offshore account. I get up every day and go to sleep every night trying to provide the best biotech coverage and commentary possible. Integral to that effort is being as interactive with you as I can, whether it's through columns like the Mailbag, live blogs, the commenting section of this web site, email or on Twitter. I want to help you make sense of this crazy, volatile biotech scene in which we're all so interested. The constant feedback, questions and comments you provide -- whether it's filled with praise or stinging with criticism -- are an invaluable and essential part of the equation. Thanks again for spending another year with me. Happy Holidays and Happy New Year! Now, onto your emails: My column elucidating the bear thesis on Clinical Data (CLDA) and its anti-depressant vilazodone prompted a response from the bulls. Wedbush analyst Greg Wade, contrary to my hedge fund source, strongly believes FDA approves vilazodone on Jan. 22 and that the drug's peak sales will top $2 billion.